EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
about
Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma.Management of advanced adult soft tissue sarcoma.Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation
P2860
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@ast
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@en
type
label
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@ast
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@en
prefLabel
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@ast
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@en
P2093
P2860
P356
P1433
P1476
EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.
@en
P2093
Crowther D
Muguiro JH
Nielsen OS
Oosterom AT
Pottelberghe CV
P2860
P304
P356
10.1080/13577149778371
P577
1997-01-01T00:00:00Z